No Data
No Data
Armada and Halliburton's Landmark Announce Global IEnergy Partner Agreement for Landmark Solutions at the Edge
Express News | Ocugen Has Completed Dosing In Third Cohort Of Phase 1/2 ArMaDa Trial For OCU410 (AAV-hRORA) For Geographic Atrophy, The Company Has Initiated Phase 2 Trial To Assess OCU410 In Larger Group Of Patients
Ocugen, Inc. Announces Completion of Dosing in Subjects With Geographic Atrophy Secondary to DAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
Lower Capex Expected From Armada's JV Deal
Navigator and Bumi Armada Partner With Uniper for CO2 Project
Bumi Armada JV Inks MOU to Explore Carbon Storage Provision in the UK
No Data